Traumakine Research Collaboration and DoD Grant
Summary
Press release, 13 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company with its lead immune oncology program bexmarilimab, also pursuing induction of CD73 for organ protection, announces it has joined a research consortium that has received a Department of Defense (DoD) Grant to investigate the use of intravenous interferon beta (Traumakine\xd2) for the prevention of ischemia-reperfusion injury in battlefield victims when using a lifesaving torniquet for the prevention of excessive blood loss. The aim of Traumakine\xd2 in this setting would be to improve survival and limb salvage by attenuating ischemia-reperfusion injury if a torniquet was needed.If the results of these upcoming pre-clinical experiments are positive, this could open an avenue for approval without extensive human clinical studies. From our learnings from previous clinical trials with Traumakine\xd2, we envision that the best outcomes with intravenous interferon beta can be achieved when the drug is used for the prevention, and not necessarily treatment, of systemic inflammation and organ damage. Forward looking statements are identified by their use of terms and phrases such as believe, could, "should", "expect", "hope", "seek", envisage, estimate, intend, may, plan, potentially, will or the negative of those, variations or comparable expressions, including references to assumptions. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors.